As a Swiss pharmaceutical company opens its first U.S. office in Massachusetts, one of its drug trials will be held in the Memphis area.
Santhera Pharmaceutials, a Swiss specialty company focused on the development of treatments for rare mitochondrial and neuromuscular diseases, will establish U.S. operations in Burlington, Massachusetts.
“A strong presence in the U.S. is an important next step in our mission to advance novel treatments for Duchenne muscular dystrophy and other rare neuromuscular…
↧